Effect of intranasal dexmedetomidine on emergence agitatio
Not Applicable
Completed
- Conditions
- Ear, Nose and ThroatSurgeryPaediatrics
- Registration Number
- PACTR201604001572340
- Lead Sponsor
- Benha university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 86
Inclusion Criteria
ASA I and II physical status.
Ages ranged between 3-7 years old.
Scheduled for an elective tonsillectomy and/ or adenoidectomy under general anaesthesia with sevoflurane.
Exclusion Criteria
Obstructive sleep apnea.
Mental retardation or developmental delay.
Chest, cardiac or neurological diseases. Known allergy or hypersensitivity to dexmedetomidine.
Patients receiving medications known to interact with dexmedetomidine such as furosemide, lorazepam, and diphenhydramine
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie intranasal dexmedetomidine's anti-agitation effects in pediatric anesthesia?
How does intranasal dexmedetomidine compare to intravenous midazolam for preventing emergence agitation in children?
Are there specific biomarkers that predict response to intranasal dexmedetomidine in pediatric tonsillectomy patients?
What are the potential adverse events associated with intranasal dexmedetomidine in children undergoing ENT surgery?
What combination therapies with intranasal dexmedetomidine show promise for managing postoperative agitation in pediatric patients?